leisure time -WSS

leisure time

author：leisure time 2025-09-30 12:17:03 - browse：5

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Senate committee scrutinizes Medicare Advantage brokers

Wikipedia

hotspot

WSS

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Impact of Dobbs ruling felt at reproductive medicine meeting

AMAs digital advisors table RPM coding reform proposal, again

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Hospital price transparency does save money, advocate argues

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

leisure time

leisure time

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

The cancer drug shortage isn’t new — and neither are the solutions

Study gives hint on South Asians’ higher risk of cardiovascular disease

23andMe had bad news about my health. I wish a person had delivered it

Studies point to risks of excluding people with obesity from drug trials

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA gives detailed accounting of AI

New air purifier tech could be key to improving indoor air quality

Impact of Dobbs ruling felt at reproductive medicine meeting

hotspot

HHS leader on health, climate change and biopharma emissions

UnitedHealth’s board chair also owns a personal investment firm

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Hospital price transparency does save money, advocate argues

STAT Summit: Michael J. Fox on progress in Parkinson's research

Juul documents reveal insider tactics on political lobbying

Wikipedia

focus

hotspot

Wikipedia